KPV reconstitution calculator
Type in a vial size, the diluent volume you added, and a dose figure — the calculator below converts those three numbers into a concentration, a draw volume, and a syringe reading. It performs the same arithmetic as our tirzepatide and sermorelin calculators. What it cannot do, for KPV specifically, is check that arithmetic against an FDA-approved product's own label, because no such label — or product — exists. Read why below before you use it.
There is no approved product or dosing standard behind this calculator
KPV — short for Lysine-Proline-Valine, the three amino acids in its name — is a tripeptide fragment of the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It has never had an FDA-approved drug product of its own: a direct check against DailyMed, the National Library of Medicine's official archive of FDA-approved drug labeling, returns zero results for "KPV." Most of the published research behind it is anti-inflammatory signaling work — rodent colitis models and skin-inflammation studies — not the kind of human dosing evidence a label is built from, and it is a chemically distinct molecule from the other peptides on this calculator, not a variant of BPC-157 or TB-500.
Its compounding status is also unsettled, and has moved recently: KPV sat on FDA's interim Section 503A Category 2 list (bulk substances presenting significant safety risks that pharmacies should not compound) from 2023 until April 15, 2026, when FDA removed it — along with eleven other peptides, including TB-500, BPC-157 and injectable GHK-Cu — because the nomination behind that listing was withdrawn, effective April 22, 2026. That removal does not make compounding KPV legal; it only lifts the "significant safety risk" flag and leaves it outside every category while further review continues. That review has already happened: at FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026, the committee voted 8-6-1 to recommend adding KPV to the 503A bulks list, alongside similar recommendations for BPC-157 and TB-500. FDA has published no minutes or vote record for that meeting; the tally comes from law-firm accounts of the public session. A committee recommendation is not final agency action — as of this page's last review, FDA had not yet formally added KPV to the list.
What the tool below actually does is narrower than that context might suggest: it takes the vial size, diluent volume, and dose you type in and returns the concentration and draw volume that arithmetic implies — nothing more. It cannot confirm that a particular vial is what its label claims, that the dose you enter is appropriate for you, that it is currently legal for a pharmacy to have compounded it, or that the product you drew that number from came from a legitimate source. A correct-looking syringe reading is not evidence that any of those things are true.
Sources: DailyMed structured-product-label search for "KPV" (zero results), FDA's April 15, 2026 removal of KPV from the interim Section 503A Category 2 bulk drug substances list, and FDA's July 23-24, 2026 Pharmacy Compounding Advisory Committee vote on KPV, all independently checked August 2026. View the DailyMed search.
KPV reconstitution
Fill in all three fields to see exactly where the plunger lands.
Where to go next
- Read what the actual published research shows — a real rodent colitis literature vs. zero published human trials — on our KPV evidence review.
- See what KPV's own foundational animal studies do — and don't — disclose about dose, on our KPV dosage article.
- Compare against the compounds this calculator supports that do have an FDA-approved reference product, on the calculator hub.
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.